Navigation Links
New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies
Date:12/18/2007

may not be effective against antibiotic-resistant strains of anthrax.

ABthrax is a human monoclonal antibody to Bacillus anthracis protective antigen that was discovered and developed by HGS, using technology that HGS has integrated into the Company as part of its collaboration with Cambridge Antibody Technology. ABthrax was the first investigational agent against anthrax infection to be evaluated in a clinical study following the 2001 anthrax attacks in the United States. In 2003, ABthrax received a Fast Track Product designation from the FDA, as well as an Orphan Drug Designation for its use in the treatment of inhalational anthrax disease.

In contrast to the anthrax vaccine, the protection afforded by a single dose of ABthrax would be immediate following the rapid achievement of appropriate blood levels of ABthrax. In contrast to antibiotics, ABthrax acts against the deadly toxins produced by anthrax bacteria. It may also prevent and treat infections by antibiotic-resistant strains of anthrax.

The ABthrax Contract with the U.S. Government

In June 2006, the U.S. Government exercised its option to purchase ABthrax for the Strategic National Stockpile (Contract Number HHS010020050006C). HGS expects to receive $165 million in revenues from this award, with the majority to come in 2008, when the Company begins to deliver ABthrax. The purchase award was made by the U.S. Department of Health and Human Services (HHS) under the Project BioShield Act of 2004, which is designed to accelerate the development, purchase and availability of medical countermeasures for the Strategic National Stockpile.

Under the contract, HGS will manufacture and deliver 20,000 treatment courses of ABthrax to the Strategic National Stockpile. The Company is also working closely with HHS, FDA and CDC to complete the additional laboratory and clinical testing required to support the filing of a Biologics License Application (BLA), and to support the use of ABthra
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Study Demonstrates Mindful Approach to Aging
2. Hillary Clinton Pledges Bold Approach to Stopping HIV/AIDS & Global Poverty
3. Raydiance Collaborates With Rutgers University and Nations Largest Tissue Bank to Develop Innovative Tissue Processing Approaches
4. Endoscopy Identified as Safe and Effective Method in Treating Common Complication of Gastric Bypass Surgery
5. New Data Show Doripenem as Effective as Commonly Used Therapies in Treating Hospital-Acquired Pneumonias
6. New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients With Complicated Skin Infections, Including MRSA
7. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
8. Promising Results in Treating Facial Bruising From Injectables
9. Evidence of Benefit Lacking for Many Common Ways of Treating Osteoarthritis of the Knee
10. New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients with Diabetic Foot Infections
11. Edwards Resilient Trial Demonstrates Statistically Superior Results for Treating Peripheral Arterial Disease in the Leg

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)... , , NATICK, Mass. and LONDON, Nov. 20 /...tion (NYSE: BSX ) today announced that it has re...g Administration (FDA) and CE Mark approval to mar...ent for the treatment of malignant esophageal stri... with resectable or non-resectable esophageal canc...
(Date:11/20/2009)... , , FRANKLIN LAKES, N.J., Nov. 20 /PRNews...ny) (NYSE: BDX ) today announced the completion ..., Michigan-based company that develops and manufac...latforms. ,, In May 2009, BD and HandyLab annou...commercialize molecular assays on the HandyLab Jag...
(Date:11/19/2009)... , , BIRMINGHAM, Ala., Nov. 19 /PRNewswi...asdaq: BCRX ) today announced the pricing of a pu...ock at $9.75 per share, resulting in gross proceed...offered by BioCryst pursuant to an effective shelf...Securities and Exchange Commission. BioCryst has ...
Breaking Medicine Technology:Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 2Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 3Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 4BD Completes Acquisition of HandyLab, Inc. 2BD Completes Acquisition of HandyLab, Inc. 3BioCryst Announces Pricing of Public Offering of Common Stock 2BioCryst Announces Pricing of Public Offering of Common Stock 3Learning Takes Place When You Get Things Right 53240 1Learning Takes Place When You Get Things Right 53240 2The First SamarionSolution Installed in Lake Charles Alzheimers Facility 53237 1The First SamarionSolution Installed in Lake Charles Alzheimers Facility 53237 2Popular Breast Cancer Drug Used with Certain Antidepressants Puts New Jersey Women at Risk 4797 1Popular Breast Cancer Drug Used with Certain Antidepressants Puts New Jersey Women at Risk 4797 2Popular Breast Cancer Drug Used with Certain Antidepressants Puts New Jersey Women at Risk 4797 3Popular Breast Cancer Drug Used with Certain Antidepressants Puts New Jersey Women at Risk 4797 4
...linically Meaningful Primary Endpoint for Clinical...World Muscle Society,Congress -, SOUTH PLAINFIELD...ay announced promising findings in patients with D... 13th International World Muscle Society,(WMS) Con...ng the utility,of the 6-minute walk test (6MWT) as...
.... 29 Obese school-age,kids and teens can lose wei...pate in medium- to high-intensity behavioral manag...today by HHS, Agency for Healthcare,Research and Q...y behavioral management,programs studied met for m...r 6 months to 12 months. Effective programs includ...
Other Medicine Technology:PTC Therapeutics Announces Data Showing Six-Minute Walk Test Consistently Measures Ambulatory Function in Patients With Duchenne Muscular Dystrophy 2PTC Therapeutics Announces Data Showing Six-Minute Walk Test Consistently Measures Ambulatory Function in Patients With Duchenne Muscular Dystrophy 3PTC Therapeutics Announces Data Showing Six-Minute Walk Test Consistently Measures Ambulatory Function in Patients With Duchenne Muscular Dystrophy 4PTC Therapeutics Announces Data Showing Six-Minute Walk Test Consistently Measures Ambulatory Function in Patients With Duchenne Muscular Dystrophy 5Behavioral Modification Programs Help Obese Children Manage Their Weight 2Behavioral Modification Programs Help Obese Children Manage Their Weight 3
(Date:11/20/2009)... Following a recall by Unilever The...sale Shedd,s Country Crock ® Side Dishes DELU... ® Side Dishes DELUXE Four Cheese Pasta due t...wing code dates and UPCs are affected: ,, Shed...r Broccoli Rice 21 oz, UPC 027400218316, Best By N...
(Date:11/20/2009)...swire-USNewswire/ -- The American Dental Associati...stration (FDA) to establish appropriate classifica... concern about the safety of whitening products th...rofessional consultation or examination by a denti...hemically based tooth whitening or bleaching agent...
(Date:11/20/2009)...v. 20 Samuel Gladding i...hat it means to be "happy" during the holidays. As...y in family counseling and chair of the Department... says research shows that it is the pressure to be...sion during the holidays. ,, That,s why he,s ch...
(Date:11/20/2009)...vember 20 in the Journal of the National Cancer I...s that often appear in news coverage of cancer res...e media and journals to help alleviate the problem...oshin, M.D., M.S., of Center for Medicine and the ... and Clinical Practice in New Hampshire, and Barne...
(Date:11/20/2009)...0, 2009Emergency medical service (EMS) providers i...rdiac arrests each year. Only 5 to 10 percent of ...tter quality cardiopulmonary resuscitation (CPR) p...ated with better patient outcome. The Resuscitati...al research network to study prehospital treatment...
Breaking Medicine News(10 mins):Health News:Stop & Shop Alerts Customers to Voluntary Recall by Unilever 2Health News:American Dental Association Petitions FDA to Classify, Regulate Tooth-Whitening Products 2Health News:Why Holidays Don't Have To Be 'Happy' 2Health News:Promoting healthy skepticism in the news: Helping journalists get it right 2Health News:Effect of real-time CPR feedback reported at resuscitation science symposium 2Health News:Effect of real-time CPR feedback reported at resuscitation science symposium 3
...f patients who undergo male to female sex-change s...t that complications are common, according to a st... the urology journal BJU International. , A rese...atients who had undergone surgery and 70 who took ...
...lif., Sept. 20 Cardiva Medical, Inc.,a privately ...Augustine,Lien, Chairman and CEO, will present at ...sday, September 25th in New York City. Notably, th...learance. This new product builds on the success o...
... 20 The American Red Cross,and American Heart Ass...n,that would designate the first week of June as "...utomated External Defibrillator (AED) Week." The,b...ty of CPR and AED training and use to reduce death...
...utive and Current Banfield President Succeeds Scot...PORTLAND, Ore., Sept. 19 Effective September 19, ... Officer of Banfield, The Pet,Hospital(R), succeed...,President, Chief Operating Officer and Acting CEO...
... Leader of the Global Breast Cancer Movement, Rece... DALLAS, Sept. 19 Ambassador Nancy G. Brinker, fo...largest breast cancer,organization, and recently a...bin/prnh/20070122/NYM084LOGO ) Each year, Forbes ...
...., Sept. 19 Neurobiological,Technologies, Inc. an...e,fiscal year ended June 30, 2007, included in the...tember 13, 2007, contain a going concern,qualifica...short term investments of approximately $8.9 milli...
Other Medicine News:Health News:Most patients who have male-to-female sex-change surgery are happy, despite complications 2Health News:Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM) 2Health News:Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM) 3Health News:Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM) 4Health News:Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM) 5Health News:National CPR/AED Awareness Week Introduced in Congress 2Health News:National CPR/AED Awareness Week Introduced in Congress 3Health News:Largest Privately-Owned Veterinary Practice in the World, Banfield, the Pet Hospital(R), Appoints New Chief Executive Officer 2Health News:Forbes Honors Susan G. Komen for the Cure Founder as Trailblazer 2Health News:Forbes Honors Susan G. Komen for the Cure Founder as Trailblazer 3Health News:Neurobiological Technologies Reports Going Concern Qualification 2
Codmans Micro Osseous Dissection Curette
Karlin XL Magnum Cup Curette
Caspar
Kerpel
Medicine Products: